What do systematic reviews say?

Psychotherapy as an adjunct to usual care vs usual care

Psychotherapy as an adjunct to usual care may leads to higher response (50% reduction in BDI) medium term (7 to 12 months)* compared with usual care alone (low certainty).

• Psychological therapies for treatment‐resistant depression in adults 2018 · Cochrane Headline outcomes only
  RR 1.73 [1.42, 2.1]
  2 studies · 475 participants
  Low

Psychotherapy as an adjunct to usual care vs usual care

Psychotherapy as an adjunct to usual care may leads to higher response (50% reduction in BDI) long term (longer than 12 months)* compared with usual care alone (low certainty).

• Psychological therapies for treatment‐resistant depression in adults 2018 · Cochrane Headline outcomes only
  RR 1.62 [1.13, 2.32]
  1 study · 248 participants
  Low

Psychotherapy as an adjunct to usual care vs usual care

Psychotherapy as an adjunct to usual care probably leads to higher remission (< 7 on HAMD or < 10 on BDI) medium term (7 to 12 months)* compared with usual care alone (moderate certainty).

• Psychological therapies for treatment‐resistant depression in adults 2018 · Cochrane Headline outcomes only
  RR 1.97 [1.51, 2.56]
  2 studies · 475 participants
  Moderate
• Psychological therapies for treatment‐resistant depression in adults 2018 · Cochrane Headline outcomes only
  RR 1.56 [0.97, 2.53]
  1 study · 248 participants
  Low

Psychotherapy as an adjunct to usual care vs usual care

Psychotherapy as an adjunct to usual care showed no clear difference in dropout short term (up to 6 months) compared with usual care alone (high certainty).

• Psychological therapies for treatment‐resistant depression in adults 2018 · Cochrane Headline outcomes only
  RR 0.85 [0.58, 1.24]
  6 studies · 698 participants
  High

Psychotherapy as an adjunct to usual care vs usual care

Psychotherapy as an adjunct to usual care may leads to higher response (50% reduction in depressive symptoms from baseline) short… compared with usual care alone (low certainty).

• Psychological therapies for treatment‐resistant depression in adults 2018 · Cochrane Headline outcomes only
  RR 1.8 [1.2, 2.69]
  4 studies · 556 participants
  Low

Psychotherapy as an adjunct to usual care vs usual care

Psychotherapy as an adjunct to usual care probably leads to higher remission (< 7 on HAMD or < 10 on BDI) short term (up to 6 months) compared with usual care alone (moderate certainty).

• Psychological therapies for treatment‐resistant depression in adults 2018 · Cochrane Headline outcomes only
  RR 1.92 [1.46, 2.52]
  6 studies · 635 participants
  Moderate

Dynamic‐Deconstructive Psychotherapy (DDP) vs treatment

• Psychological therapies for people with borderline personality disorder 2012 · Cochrane Headline outcomes only
  no estimate extracted
  1 study · 30 participants
  Low

Dynamic‐Deconstructive Psychotherapy (DDP) vs treatment

Dynamic‐Deconstructive Psychotherapy (DDP) showed no clear difference in parasuicidalityno. of participants with parasuicide (last 3 months) compared with treatment (low certainty).

• Psychological therapies for people with borderline personality disorder 2012 · Cochrane Headline outcomes only
  RR 0.89 [0.47, 1.67]
  1 study · 30 participants
  Low

Dynamic‐Deconstructive Psychotherapy (DDP) vs treatment

• Psychological therapies for people with borderline personality disorder 2012 · Cochrane Headline outcomes only
  no estimate extracted
  1 study · 30 participants
  Low

Summary of findings ‐ monotherapy: lumacaftor vs placebo

• Corrector therapies (with or without potentiators) for people with cystic fibrosis with class II CFTR gene variants… 2023 · Cochrane Headline outcomes only
  no estimate extracted
  2 studies · 147 participants
  Low

Summary of findings ‐ monotherapy: lumacaftor vs placebo

The review found no eligible studies for this question.

• Corrector therapies (with or without potentiators) for people with cystic fibrosis with class II CFTR gene variants… 2023 · Cochrane Headline outcomes only
  no estimate extracted
  Studies not reported
  No studies found

Summary of findings ‐ monotherapy: lumacaftor vs placebo

• Corrector therapies (with or without potentiators) for people with cystic fibrosis with class II CFTR gene variants… 2023 · Cochrane Headline outcomes only
  no estimate extracted
  1 study · 85 participants
  Low

Summary of findings ‐ monotherapy: lumacaftor vs placebo

The review found no eligible studies for this question.

• Corrector therapies (with or without potentiators) for people with cystic fibrosis with class II CFTR gene variants… 2023 · Cochrane Headline outcomes only
  no estimate extracted
  Studies not reported
  No studies found

Summary of findings ‐ monotherapy: lumacaftor vs placebo

• Corrector therapies (with or without potentiators) for people with cystic fibrosis with class II CFTR gene variants… 2023 · Cochrane Headline outcomes only
  no estimate extracted
  1 study · 61 participants
  Moderate

Summary of findings ‐ monotherapy: lumacaftor vs placebo

• Corrector therapies (with or without potentiators) for people with cystic fibrosis with class II CFTR gene variants… 2023 · Cochrane Headline outcomes only
  no estimate extracted
  2 studies · 115 participants
  Very low

Summary of findings ‐ monotherapy: lumacaftor vs placebo

The review found no eligible studies for this question.

• Corrector therapies (with or without potentiators) for people with cystic fibrosis with class II CFTR gene variants… 2023 · Cochrane Headline outcomes only
  no estimate extracted
  Studies not reported
  No studies found

Summary of findings ‐ monotherapy: cavosonstat vs placebo

• Corrector therapies (with or without potentiators) for people with cystic fibrosis with class II CFTR gene variants… 2023 · Cochrane Headline outcomes only
  no estimate extracted
  1 study · 24 participants
  Very low

Summary of findings ‐ monotherapy: cavosonstat vs placebo

The review found no eligible studies for this question.

• Corrector therapies (with or without potentiators) for people with cystic fibrosis with class II CFTR gene variants… 2023 · Cochrane Headline outcomes only
  no estimate extracted
  Studies not reported
  No studies found

Summary of findings ‐ monotherapy: cavosonstat vs placebo

• Corrector therapies (with or without potentiators) for people with cystic fibrosis with class II CFTR gene variants… 2023 · Cochrane Headline outcomes only
  no estimate extracted
  1 study · 26 participants
  Very low

Summary of findings ‐ monotherapy: cavosonstat vs placebo

• Corrector therapies (with or without potentiators) for people with cystic fibrosis with class II CFTR gene variants… 2023 · Cochrane Headline outcomes only
  no estimate extracted
  1 study · 26 participants
  Very low